Association between metabolic syndrome and salivary MMP ‐8, myeloperoxidase in periodontitis
Oral Diseases · 2025-01 · 31 (1) · 225-238
DOI: 10.1111/odi.15014 ↗Kurz gefasst
Fachartikel in der Zeitschrift Oral Diseases, online erschienen am 09.06.2024. Verfasst von Julie Toby Thomas und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. Hauptthemen laut MEDLINE: Matrix Metalloproteinase 8, Metabolic Syndrome, Peroxidase, Periodontitis. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study investigated the effect of metabolic syndrome (MetS) on periodontal clinical parameters and salivary biomarkers' matrix metalloproteinase‐8 (MMP‐8) and myeloperoxidase (MPO) in patients with periodontitis.
Methods
A total of 120 participants aged 25–55 were categorized into three groups: MetS with periodontitis ( n = 40); systemically healthy with periodontitis ( n = 40); and systemically and periodontally healthy controls ( n = 40). Data collected included systemic parameters like waist circumference (WC), blood pressure (BP), high‐ and low‐density lipoproteins, triglycerides (TG), fasting blood sugar (FBS), and glycated hemoglobin (HbA1c). Periodontal parameters estimated included bleeding on probing score (BoP), full‐mouth plaque score (FMPS), periodontal probing depth (PPD), clinical attachment loss (CAL), and the number of missing teeth. Unstimulated whole saliva was analyzed via ELISA for active MMP‐8 (aMMP‐8), total MMP‐8 (tMMP‐8), and MPO.
Results
Participants with MetS and periodontitis exhibited significantly higher periodontal parameters, salivary aMMP‐8, and MPO (26.26 vs. 24.1 ng/mL and 13.53 vs. 11.55 ng/mL compared to systemically healthy periodontitis patients) (all p < 0.01). Positive correlations occurred between aMMP‐8 and WC, TG, and FBS ( p < 0.01), and between MPO and WC, BP, and TG ( p < 0.01).
Conclusions
The positive associations between these biomarkers and metabolic parameters indicate their potential utility for monitoring cardiovascular and glycemic risk in patients with periodontal disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
- Department of Periodontics, Saveetha Dental College and Hospitals, Saveetha Institute of Medical and Technical Sciences, Chennai, Tamilnadu, India.
- Department of General Medicine, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, Kerala, India.
- Department of Periodontics, Pushpagiri College of Dental Sciences, Thiruvalla, Kerala, India.
- Department of Statistics, Women's College, Trivandrum, Kerala, India.
- Division of Periodontology, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Julie Toby Thomas, Betsy Joseph
Zitieren
APA
Thomas, J. T., Joseph, B., Varghese, S., Thomas, N. G., Kamalasanan Vijayakumary, B., Sorsa, T., Anil, S., & Waltimo, T. (2025). Association between metabolic syndrome and salivary MMP ‐8, myeloperoxidase in periodontitis. Oral Diseases, 31(1), 225-238. https://doi.org/10.1111/odi.15014
Vancouver
Thomas JT, Joseph B, Varghese S, Thomas NG, Kamalasanan Vijayakumary B, Sorsa T, et al. Association between metabolic syndrome and salivary MMP ‐8, myeloperoxidase in periodontitis. Oral Diseases. 2025;31(1):225-238. doi:10.1111/odi.15014
BibTeX
@article{Thomas2025,
author = {Thomas, Julie Toby and Joseph, Betsy and Varghese, Sajit and Thomas, Nebu George and Kamalasanan Vijayakumary, Baiju and Sorsa, Timo and Anil, Sukumaran and Waltimo, Tuomas},
title = {Association between metabolic syndrome and salivary MMP ‐8, myeloperoxidase in periodontitis},
journal = {Oral Diseases},
year = {2025},
volume = {31},
number = {1},
pages = {225--238},
doi = {10.1111/odi.15014}
}
EUVIMED